BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.9639
-0.0961 (-9.07%)
At close: Nov 20, 2026, 4:00 PM EST
0.9900
+0.0261 (2.71%)
After-hours: Nov 20, 2026, 7:30 PM EST
BioLineRx Revenue
BioLineRx had revenue of $294.00K in the quarter ending June 30, 2026, a decrease of -3.29%. This brings the company's total for the last twelve months to $1.39M, down -91.93% year-over-year. In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%.
Revenue (ttm)
$1.39M
Revenue Growth
-91.93%
P/S Ratio
6.42
Revenue / Employee
$58,000
Employees
24
Market Cap
8.93M
Revenue by Geography
- China 14.96M 51.7%
- U.s. 13.98M 48.3%
Fiscal year ended Dec 31, 2024 See the full BioLineRx breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 4.70M |
| CytoMed Therapeutics | 609.73K |
| Lexaria Bioscience | 194.00K |
| aTyr Pharma | 190.00K |
| Vyome Holdings | 153.10K |
| Lisata Therapeutics | 100.00K |
BLRX News
- 3 days ago - BioLineRx Ltd. Enters into $5.6 Million Royalty Monetization Transaction - Nasdaq
- 3 days ago - BioLineRx to Report Third Quarter 2026 Results on November 23, 2026 - PRNewsWire
- 3 days ago - BioLineRx enters $5.6M royalty monetization deal with Soleus Capital - TheFly
- 3 days ago - BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital - PRNewsWire
- 5 days ago - BioLineRx Ltd. and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates at SNO 2026 - Nasdaq
- 5 days ago - BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 - PRNewsWire
- 4 weeks ago - BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 - PRNewsWire
- 6 weeks ago - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day - PRNewsWire